Lenalidomide combined with intensive chemotherapy in acute myeloid leukemia and higher-risk myelodysplastic syndrome with 5q deletion. Results of a phase II study by the Groupe Francophone Des Myélodysplasies

Patients with acute myeloblastic leukemia or higher risk myelodysplastic syndromes with 5q deletion (generally within a complex karyotype) respond poorly to intensive chemotherapy and have very poor survival. In this population, we evaluated escalating doses of lenalidomide combined with intensive c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ades, Lionel, Prebet, Thomas, Stamatoullas, Aspasia, Recher, Christian, Guieze, Romain, Raffoux, Emmanuel, Bouabdallah, Krimo, Hunault, Mathilde, Wattel, Eric, Stalnikiewicz, Laure, Toma, Andrea, Dombret, Hervé, Vey, Norbert, Sebert, Marie, Gardin, Claude, Chaffaut, Cendrine, Chevret, Sylvie, Fenaux, Pierre
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395113/
https://www.ncbi.nlm.nih.gov/pubmed/28034993
http://dx.doi.org/10.3324/haematol.2016.151894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395113/
https://www.ncbi.nlm.nih.gov/pubmed/28034993
http://dx.doi.org/10.3324/haematol.2016.151894

Ejemplares similares